Abstract: Polypeptide pharmaceutical compositions having improved stability and resistance to aggregation, particle formation and precipitation comprising a polypeptide pharmaceutical and poloxamer surfactants alone, or in combination with polysorbate surfactants. Preferred polypeptides stabilized are bactericidal/permeability increasing (BPI) protein, biologically active fragments of BPI, biologically active analogs of BPI, and biologically active variants of BPI.

Abstract: Polypeptide pharmaceutical compositions having improved stability and resistance to aggregation, particle formation and precipitation comprising a polypeptide pharmaceutical and poloxamer surfactants alone, or in combination with polysorbate surfactants. Preferred polypeptides stabilized are bactericidal/permeability increasing (BPI) protein, biologically active fragments of BPI, biologically active analogs of BPI, and biologically active variants of BPI.

Abstract: Polypeptide pharmaceutical compositions having improved stability and resistance to aggregation, particle formation and precipitation comprising a polypeptide pharmaceutical and poloxamer surfactants alone, or in combination with polysorbate surfactants. Preferred polypeptides stabilized are bactericidal/permeability increasing (BPI) protein, biologically active fragments of BPI, biologically active analogs of BPI, and biologically active variants of BPI.

Abstract: Polypeptide pharmaceutical compositions having improved stability and resistance to aggregation, particle formation and precipitation comprising a polypeptide pharmaceutical and poloxamer surfactants alone, or in combination with polysorbate surfactants. Preferred polypeptides stabilized are bactericidal/permeability increasing (BPI) protein, biologically active fragments of BPI, biologically active analogs of BPI, and biologically active variants of BPI.

Abstract: Bactericidal/permeability increasing (BPI) polypeptide pharmaceutical compositions having improved stability and resistance to aggregation, particle formation and precipitation comprising the polypeptide pharmaceutical and poloxamer surfactants alone, or in combination with polysorbate suractants. Preferred BPI polypeptides stabilized are bactericidal/permeability increasing (BPI) protein, biologically active fragments of BPI, and biologically active analogs of BPI.

Abstract: Surgically implantable skeletal ligament having secured thereto at least one deformable collar having a velour-like outer surface adapted to invite tissue ingrowth. In use, the collar portion of the ligament is positioned within a surgically prepared passageway in a bone to protect the ligament from bone abrasion and to assist in ligament attachment by accepting tissue ingrowth into the velour-like surface.

Abstract: A prosthesis for replacement of a damaged joint or load-bearing structure in an animal or human body comprises a shaped structural member, a relatively thick or cushioning coating of a physiologically inert elastomer over the surfaces of the structural member in load-bearing relationship with the skeletal structure of the body, and an open-pore, tissue-ingrowth-receptive fabric coating the elastomer, all elements being firmly bonded to each other. In many embodiments, a stem of the prosthesis comprising the above elements is adapted to be inserted into a bone cavity, and is eventually affixed firmly thereto by fibrous tissue and bony ingrowth. Stability of the stem portion is enhanced by buttresses integral with the base of the stem.